AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03126851 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Label
Description: Labels vary based on presence or absence of age range information, and inclusion of an explicit warning in words, with or without a pictographic icon.
Study NCT01946087 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Remote ischemic preconditioning at left upper arm
Description: Placement of automated cuff-inflator on the left upper arm after induction of anesthesia RIPCgroup-3 cycles of 5 min ischemia (300 mmHg inflation) \& 5 min reperfusion (deflation)
Study NCT01946087 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Control group
Description: keeping the cuff deflated
Study NCT01672307 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Minoxidil lotion 2%
Description: Minoxidil lotion 2% is applied twice daily to one eyebrow.
Study NCT01672307 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is applied twice daily to the other eyebrow.
Study NCT01887860 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cetaphil Daily Facial Moisturizer SPF 50
Description: Other: Cetaphil Daily Advance Ultra Hydrating Lotion 0.2ml or 0.2g of Cetaphil on occlusive, hypoallergenic patch applied to skin for 24 hrs 9 times on Monday, Wednesday, and Friday for 3 weeks
Study NCT00897429 — intervention group
Intervention type: PROCEDURE
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01412073 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oxytocin
Description: group I : oxytocin 5 IU bolus over 3 minutes after delivery of the baby group II : oxytocin 5 IU bolus over 3 minutes after delivery of the baby and oxytocin infusion in 500 ml 0.9% saline over 4 hours
Study NCT01412073 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: misoprostol intrauterine 800 microgram placed intrauterine after delivery of the baby \& the placenta
Study NCT00709020 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: white button mushroom extract
Description: Dose escalation with six evaluable subjects per dose level. Doses begin at 5 g/day, then 8 g/day, then 10 g/day then 13 g/day.
Study NCT01836471 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QAW039
Description: QAW039 supplied as hard gelatin capsule in unit dose strength of 150 mg. Patient took 450 mg once daily (3 capsules taken with food in the morning) for the approximate period of the study (12 weeks)
Study NCT00709020 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: flow cytometry
Description: Performed on blood samples taken day -14 and -7 prior to treatment and days 1, 8, 15, 29, 57 and 85 of treatment.
Study NCT00709020 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high performance liquid chromatography
Description: Performed on blood samples taken day -14 and -7 prior to treatment and days 1, 8, 15, 29, 57 and 85 of treatment.
Study NCT00709020 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Performed on blood samples taken pre-treatment on day 1 and on day 85 after treatment.
Study NCT00709020 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mass spectrometry
Description: Performed on blood samples taken day -14 and -7 prior to treatment and days 1, 8, 15, 29, 57 and 85 of treatment.
Study NCT00709020 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacogenomic studies
Description: Performed on blood samples taken on days 1, 8, 15, 29, 57 and 85 of treatment.
Study NCT00709020 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Performed on blood samples taken pre-dose and at 0.25, 0.5, 0.75, 1, 2, 4 and 6 hours after White Button Mushroon extract on day 1 of treatment and pre-dose on days 8, 15, 29, 57 and 85 after start of treatment.
Study NCT03797365 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Classical rehabilitation
Description: Participants will benefit from two-phases perineal rehabilitation:~First phase will include the PFM's awareness and voluntary contraction learning with manual, biofeedback technics and functional electro stimulation. These exercises will call out the manual rehabilitation technics, biofeedback and electro stimulation. Each classical rehabilitation session will take 30 minutes with 20 minutes of active working, twice per week. About the self-training, there will be no consensus for optimal homemade exercises.~For the second phase, a behavior analyze will be summarized in order to update the favoring and inappropriate situations. The strategy put in place will be organized in unlearning of deleterious perineal habits and learning new behavior program. The main goal will be the perineal locking set up, which must be systematic before and during efforts. During this phase, the physiotherapist will twice weekly perform evaluations (similar to those in the first phase)
Study NCT03797365 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive associated rehabilitation
Description: The cognitive associated rehabilitation group randomized participants will have to execute twice a day the rehabilitation protocol. Each cognitive rehabilitation session will take three minutes. Participants will have to synergistically execute attentional tests (N-Back Test) and execute a perineal contraction during the contraction instructions. (10 randomized auditory stimuli in three minutes). The attentional tests' difficulty will be gradually increased each 15 days. N-Back Test modalities are the followings: the participant will visualize a series of random numbers. First difficulty step will be to click the dedicated button when the volunteer will see the indicated letter. The second difficulty step will be to click the dedicated button when she will see two consecutives times the same letter. The third difficulty step will be to click the dedicated button when she will see two times the same letter separated by one different letter, and so on...
Study NCT01836471 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo QAW039
Description: Matching placebo for QAW039 supplied as hard gelatin capsule were identical in appearance to their active counterparts. Patients took 3 QAW039 matching placebo capsules once a day ( taken with food in the morning) for the approximate period of the study (12 weeks)
Study NCT02493088 — intervention group
Intervention type: OTHER
Intervention: Antisocial personality recording of behavior and contextual elements
Description: aberrant driving behaviors and upstream contextual elements of individuals diagnosed with antisocial personality disorder will be recorded during the study
Study NCT01233193 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health education, Home blood pressure monitoring
Description: Health education (on hypertension, smoking, healthy diet, obesity, physical inactivity and adherence to antihypertensive medications and home blood pressure monitoring) . The patient will be referred to physician when needed. The patient will be followed up during 6 months.
Study NCT01836471 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo QAW039
Description: Matching placebo for QAW039 supplied as hard gelatin capsule were identical in appearance to their active counterparts. Patients took 3 QAW039 matching placebo capsules once a day ( taken with food in the morning) for the approximate period of the study (12 weeks)
Study NCT00475111 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavior Therapy for Pain (CBT-P)
Study NCT00475111 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness Meditation for Emotion Regulation (MM-ER)
Study NCT00475111 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Rheumatoid arthritis education
Study NCT01836471 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fluticasone 250 mcg
Description: Fluticasone was supplied in inhalers with dose strength of 250 mcg. Patients took 250 mcg bid (morning and evening approximately 12 hours between doses) for a total dose of 500 mcg daily for the approximate period of the study (12 weeks).
Study NCT01836471 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Fluticasone 100 mcg
Description: Background therapy - fluticasone was supplied in inhalers with dose strength of 100 mcg. All patients in the study other than the Atopic Fluticasone 150 mcg arm were given the 100 mcg dose strength inhalers and took fluticasone 100 mcg bid (taken morning and evening with approximately 12 hours between doses) as background therapy for the approximate period of the study (12 weeks).
Study NCT01836471 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluticasone 100 mcg
Description: Background therapy - fluticasone was supplied in inhalers with dose strength of 100 mcg. All patients in the study other than the Atopic Fluticasone 150 mcg arm were given the 100 mcg dose strength inhalers and took fluticasone 100 mcg bid (taken morning and evening with approximately 12 hours between doses) as background therapy for the approximate period of the study (12 weeks).
Study NCT01955928 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Online Cognitive behavioral treatment for insomnia
Study NCT01169844 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AIN457A
Study NCT04692311 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: an intelligent client-centred task-oriented training
Description: 3 x 45min of training with i-ACT system
Study NCT04692311 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Semi-structured interview
Description: Participants, patients and therapists, were invited to a semi-structured interview after training period.
Study NCT04692311 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Semi-structured interview
Description: Participants, patients and therapists, were invited to a semi-structured interview after training period.
Study NCT03535792 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl/Hyperbaric bupivacaine
Description: Intrathecal Fentanyl/Hyperbaric bupivacaine and Tibial internal fixation.
Study NCT03535792 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nalbuphine/Hyperbaric bupivacaine
Description: Intrathecal Nalbuphine/Hyperbaric bupivacaine and Tibial internal fixation.
Study NCT02429063 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bright White Light
Description: The light will be administered via a Litebook Elite or Litebook Advantage (Litebook®, Ltd., Medicine Hat, Canada). The Litebook® is a small (6×5×1 in.) and lightweight (8 oz.) box and will be fitted with adherence monitors to record at what time and for what duration the light box is turned on. The Litebook® is designed to be placed on a table approximately 18 inches from the participant's head and within 45° of the midline of the visual field. The BWL Litebook® looks identical to the DRL and utilizes 24 white light-emitting diode (LED) lights and does not emit ultraviolet light.
Study NCT02429063 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dim Red Light
Description: The light will be administered via a Litebook Elite or Litebook Advantage (Litebook®, Ltd., Medicine Hat, Canada). The Litebook® is a small (6×5×1 in.) and lightweight (8 oz.) box and will be fitted with adherence monitors to record at what time and for what duration the light box is turned on. The Litebook® is designed to be placed on a table approximately 18 inches from the participant's head and within 45° of the midline of the visual field. The DRL Litebook looks identical to the BWL box and contains red lights rather than white LED lights.
Study NCT04198662 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Cryoneurolysis with a Painblocker (Epimed International, Farmers Branch, Texas)
Description: The cryoneurolysis device will be triggered using 2 cycles of 2-minute gas activation separated by 1-minute defrost periods. For active probes, the nitrous oxide will be deployed to the tip where a drop in temperature to -70°C will result in cryoneurolysis.
Study NCT04198662 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Intercostal nerve block ropivacaine with epinephrine
Description: 3 mL of ropivacaine 0.5% (with epinephrine) will be injected perineurally to provide the intercostal nerve block(s)
Study NCT02015611 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin D
Description: 2,000 IU/ day of Vitamin D3
Study NCT02015611 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT04733066 — intervention group
Intervention type: DRUG
Intervention: Teduglutide
Description: Intervention group consists of patients, who receive teduglutide within routine medical care
Study NCT02478762 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Normal glycemic control
Description: Use diet, physical exercise of insulins to reach normal glycemic control.
Study NCT02478762 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Low glycemic control
Description: Use diet, physical exercise of insulins to reach low glycemic control.
Study NCT00004208 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ATG + CSA
Description: Mérieux; horse antithymocyte globulin (ATG) + Cyclosporine A (CSA)
Study NCT00004208 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Supportive care
Description: Patients randomized to this arm will be treated as outpatients.
Study NCT01207024 — intervention group
Intervention type: OTHER
Intervention: knee MRI
Description: knee MRI before surgery (inclusion) and one year after
Study NCT00766012 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2066
Description: Oral solution administered orally once per day on day 1, and then day 3 through to day 12 for the first and second dose panels and day 5 through to day 14 for the third and fourth dose panels. For the fifth and sixth panels, oral solution administered once per day on day 1, and then day 5 through to day 16. Specific dose depends on dose panel.
Study NCT00766012 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral solution administered orally once per day on day 1, and then day 3 through to day 12 for the first and second dose panels and day 5 through to day 14 for the third and fourth dose panels. For the fifth and sixth panels, oral solution administered once per day on day 1, and then day 5 through to day 16.
Study NCT03126968 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Topical epinephrine
Description: Prophylactic topical epinephrine
Study NCT00376259 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: telbivudine
Description: 600mg/day oral tablet for 96 weeks
Study NCT03126968 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Topical placebo (normal saline)
Study NCT02724319 — intervention group
Intervention type: DEVICE
Intervention: SpartanRX
Description: A buccal swap genetic sample will be collected from eligible patients who provide written informed consent for CYP2C19 testing. Genotyping will be performed by the SpartanRX system as a clinical test at the UF Health Pathology Laboratory in Jacksonville.
Study NCT04432766 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAT2020
Description: After a cohort completes the study on Day 28, data on safety and tolerability for each cohort will be evaluated by the Safety Monitoring Committee (SMC). Administration of the next higher dose to a new dosing cohort will be permitted only if adequate safety and tolerability have been demonstrated. If encouraging clinical benefit is observed at a certain dose level, the study may proceed to a to Part 2 based on emerging data.
Study NCT01692860 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Energy Restriction
Description: Subjects consume 750 kcal/d of energy below their need
Study NCT01692860 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Energy Restriction
Description: Subjects consume 750 kcal/d of energy below their need
Study NCT04198662 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham cryoneurolysis with a Painblocker
Description: The cryoneurolysis device will be triggered using 2 cycles of 2-minute gas activation separated by 1-minute defrost periods. For the sham probes, the nitrous oxide will be vented prior to reaching the probe shaft, resulting in a lack of perineural temperature change.
Study NCT04198662 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo intercostal nerve block with normal saline
Description: 3 mL of normal saline will be injected perineurally to provide placebo intercostal nerve blocks
Study NCT02555046 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Local Anesthesia
Description: Use of unspecified local anaesthesia (fx lidocain or bupivacaine)
Study NCT02009475 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interval exercise training
Study NCT02009475 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Continues aerobic training
Study NCT01169844 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: AIN457A
Study NCT00710424 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sativex
Description: containing THC (27 mg/ml):CBD (25 mg/ml), in ethanol:propylene glycol (50:50) excipients, with peppermint oil (0.05%) flavouring. Maximum permitted dose was eight actuations in any three hour period and 24 actuations (THC 65 mg: CBD 60 mg) in 24 hours
Study NCT00710424 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: containing peppermint oil, 0.05% (v/v), quinoline yellow, 0.005% (w/v), sunset yellow, 0.0025% (w/v), in ethanol:propylene glycol (50:50) excipient.
Study NCT03595345 — intervention group
Intervention type: PROCEDURE
Intervention: Liver transplantation
Description: Liver transplantation
Study NCT01169844 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Other
Study NCT01290367 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Single Dose MPCs Injection
Description: Injection of Low Dose MPCs with Hyaluronic Acid into the degenerated lumbar disc's nucleus pulposus.
Study NCT01290367 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Single injection of saline solution
Description: Intradiscal control injection with saline solution
Study NCT01290367 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Single injection of hyaluronic acid
Description: Intradiscal control injection with hyaluronic acid
Study NCT01290367 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Single Dose MPCs Injection
Description: Injection of HighDose MPCs with Hyaluronic Acid into the degenerated lumbar disc's nucleus pulposus.
Study NCT02719782 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Biological: TCR-T
Description: Autologous T cells transfected with mRNA encoding HBV antigen-specific TCR
Study NCT03701750 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Low Molecular Weight Heparin (enoxaparin sodium)
Description: enoxaparin sodium 40mg/day subcutaneously after oocyte collection, and routine luteal phase support after embryo transfer until clinical pregnancy confirmed by ultrasound
Study NCT00178490 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High blood pressure treatment
Description: Participants who are identified as having high blood pressure will be given by a pediatric nephrologist a 12-month treatment plan for their high blood pressure. The treatment plan will include a combination of diet, weight loss, increased exercise, and if needed, blood pressure medication. Participants receiving medication treatment will be treated with a calcium channel blocker and/or ACE inhibitor.
Study NCT04638790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 25 mg/m2 i.v. day 1,15 for ABVD/AVD
Study NCT04638790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bleomycin
Description: 10,000 units/m2 i.v. days 1,15 for ABVD
Study NCT04638790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vinblastine
Description: 6 mg/m2 i.v. days 1,15 for ABVD/AVD
Study NCT04638790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacarbazine
Description: 375 mg/m2 i.v. days 1,15 for ABVD/AVD
Study NCT04638790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: 100 mg/m2 i.v. days 1-3
Study NCT04638790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 50 mg/m2 i.v. day 1 for EACODD-14
Study NCT04638790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 650 mg/m2 i.v. day 1
Study NCT04638790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: 1,4 mg/m2 i.v. day 8
Study NCT04638790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 20 mg i.v. days 1-3
Study NCT04638790 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacarbazine
Description: 375 mg/m2 i.v. day 1 for EACODD-14
Study NCT03923114 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: Ga-68-NODAGA-exendin-4 PET/CT
Description: PET/CT imaging after injection with Ga-68-NODAGA-exendin-4
Study NCT02239692 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PICOPREP
Description: Sodium Picosulfate, Magnesium Oxide and Citric Acid as PICOPREP powder for oral solution
Study NCT02239692 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PICOPREP
Description: Sodium Picosulfate, Magnesium Oxide and Citric Acid as PICOPREP powder for oral solution
Study NCT02176642 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxybutynin extended release
Description: 5mg tablet taken by mouth daily for 6 weeks